Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma

Blood Adv. 2019 Oct 22;3(20):3132-3135. doi: 10.1182/bloodadvances.2019000526.

¹ Division of Hematology, Department of Medicine, University of Colorado School of Medicine, Denver, CO.
² SWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA.
³ Department of Hematology/Hematopoietic Cell Transplantation, City of Hope, Duarte, CA.
⁴ Department of Laboratory Medicine and Pathology, Mayo Clinic, Phoenix, AZ.
⁵ Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI.
⁶ Division of Hematology/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC.
⁷ James P. Wilmot Cancer Center, Division of Hematology and Oncology, University of Rochester, Rochester, NY.
⁸ Division of Hematology and Oncology, University of Michigan Cancer Center, Dexter, MI.
⁹ Division of Hematology and Oncology, Weill Cornell Medicine, New York, NY.
¹⁰ Department of Medicine, Washington University School of Medicine, St. Louis, MO.
¹¹ Wilmot Cancer Institute, University of Rochester, Rochester, NY; and.
¹² Section of Hematology/Oncology, University of Chicago, Chicago, IL.

Abstract

Five-year follow-up of S1106 demonstrates similar efficacy, MRD negativity, and 5-year survival with RH or RB, but RH was more toxic than RB.
RB showed excellent efficacy and survival and less toxicity compared with a cytarabine-based regimen in transplant-eligible MCL patients.